



**EISAI RECEIVES APPROVAL FOR TWICE-DAILY DOSING OF  
PROTON PUMP INHIBITOR PARIET® FOR TREATMENT OF REFLUX ESOPHAGITIS**

*Offers New Option to Patients Unable to Obtain  
Satisfactory Relief with Conventional Proton Pump Inhibitor Treatment*

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it has received approval in Japan for additional twice-daily 10 mg and twice-daily 20 mg dosage and administration of its proton pump inhibitor Pariet® (generic name: rabeprazole sodium) for the treatment of

---

*hwa*



**[Notes to editors]**

**1. Reflux Esophagitis Additional Dosage and Administration**

**1) Product Name**

Pariet ® Tablets 10 mg, Pariet ® Tablets 20 mg

**2) Approved Additional Dosage and Administration**

(Underlined wording indicates newly approved dosage and administration)

<Reflux Esophagitis>

The usual adult dose for oral use is 10 mg of rabeprazole sodium administered once daily. However, the dosage may be increased up to 20 mg orally once daily depending on the severity of symptoms. The usual administration should be restricted to up to 8 weeks. For patients who have not healed after 8 weeks of proton pump inhibitor treatment, a 10 mg or 20 mg dose of rabeprazole sodium may be administered orally twice daily for an additional 8 weeks. However, a twice daily 20 mg dose should only be administered to patients with severe mucosal break.

For the maintenance therapy of reflux esophagitis showing repeated recurrence and recrudescence, the dose for oral use is 10 mg once daily.